Winning Stock Forecast: Nektar Therapeutics (NASDAQ: NKTR) Up 340.47% In 1-Year As Forecasted Amid Its Stock Volatility
Winning Stock Forecast: Nektar Therapeutics (NASDAQ: NKTR) Up 340.47% In 1-Year As Forecasted Amid Its Stock Volatility
[Source: Live Trading News, May 23, 2018]
“Already, this year to-date, we have achieved multiple successes with our pipeline of Nektar invented medicines across three therapeutic areas, immuno-oncology, immunology and pain. In the area of chronic pain, we will submit the NDA for NKTR-181 to the FDA this month”
— Howard Robin – President and CEO of Nektar Therapeutics
Summary
- Over the past year NKTR went up 340.47%
- They are one of the most robust growers investors more so during the past 12 months – due to many catalysts powering the firm.
- Nektar recently commenced the phase 1B study of NKTR-358 for systemic lupus erythematosus.
- If the mentioned drug can post robust clinical outcomes as prognosticated, it can cut into the $45.5B autoimmune diseases market to deliver significantly more upsides for Nektar.
Over the past year, from May 21 2017 through May 21 2018, NKTR produced a whopping 340.47% return to investors. Nektar Therapeutics is one of the most robust growers investors
